Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,923
  • Shares Outstanding, K 162,033
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,650 K
  • 60-Month Beta 2.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.88
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.15
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +2,497,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.23 +13.17%
on 06/14/19
0.35 -25.42%
on 06/04/19
-0.03 (-11.61%)
since 05/24/19
3-Month
0.23 +13.17%
on 06/14/19
0.61 -57.33%
on 04/02/19
-0.24 (-48.25%)
since 03/22/19
52-Week
0.23 +13.17%
on 06/14/19
0.87 -69.91%
on 09/26/18
-0.37 (-58.68%)
since 06/22/18

Most Recent Stories

More News
Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced its presence at the upcoming SNMMI or Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting being held...

ATNM : 0.26 (unch)
Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") presented new data from the ongoing pivotal Phase 3 SIERRA study of Iomab-B's single agent effect in patients with active, relapsed or...

ATNM : 0.26 (unch)
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA...

ATNM : 0.26 (unch)
Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Niva Almaula, Ph.D. as Chief Business Officer, effective immediately. Dr. Almaula joins Actinium with...

NVS : 92.80 (+0.34%)
ATNM : 0.26 (unch)
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to...

ATNM : 0.26 (unch)
New Research: Key Drivers of Growth for Newmark Group, Moody's, Children's Place, Everbridge, Heska, and Actinium Pharmaceuticals -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Newmark Group, Inc. (NASDAQ:NMRK),...

HSKA : 84.06 (+0.27%)
EVBG : 89.69 (-3.36%)
MCO : 195.11 (+0.28%)
PLCE : 90.67 (-3.01%)
NMRK : 8.73 (-1.02%)
ATNM : 0.26 (unch)
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today highlighted its broad presence at the 11th Targeted-Alpha-Therapy International Symposium (TAT) that was held on April 1 - 4, 2019 in Ottawa,...

ATNM : 0.26 (unch)
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

ALPN : 4.50 (+1.81%)
OTIC : 2.56 (-0.78%)
MTEM : 8.13 (-1.81%)
TCDA : 35.00 (+1.80%)
ATNM : 0.26 (unch)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 21.25 (-1.25%)
ACRX : 2.31 (-1.70%)
ALPN : 4.50 (+1.81%)
OTIC : 2.56 (-0.78%)
MTEM : 8.13 (-1.81%)
TCDA : 35.00 (+1.80%)
ATNM : 0.26 (unch)
Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) highlighted data from its poster presentation at the AACR or American Association of Cancer Research annual Meeting 2019 demonstrating that the targeted...

ATNM : 0.26 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATNM with:

Business Summary

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition...

See More

Key Turning Points

2nd Resistance Point 0.28
1st Resistance Point 0.27
Last Price 0.26
1st Support Level 0.25
2nd Support Level 0.24

See More

52-Week High 0.87
Fibonacci 61.8% 0.62
Fibonacci 50% 0.55
Fibonacci 38.2% 0.47
Last Price 0.26
52-Week Low 0.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar